[HTML] springer.comFull View

[HTML][HTML] Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical …

C Gabriele, F Aracri, LE Prestagiacomo, MA Rota… - Clinical Proteomics, 2023 - Springer
Abstract Background Prostate Cancer (PCa) represents the second leading cause of cancer-
related death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa …
被引用次数：3 相关文章

Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

C Gabriele, F Aracri, LE Prestagiacomo… - CLINICAL …, 2023 - iris.uniecampus.it
Background: Prostate Cancer (PCa) represents the second leading cause of cancer-related
death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa …
[HTML] nih.gov

[HTML][HTML] Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical …

C Gabriele, F Aracri, LE Prestagiacomo… - Clinical …, 2023 - ncbi.nlm.nih.gov
Background Prostate Cancer (PCa) represents the second leading cause of cancer-related
death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa …

Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

C Gabriele, F Aracri, LE Prestagiacomo… - CLINICAL …, 2023 - iris.unical.it
Background: Prostate Cancer (PCa) represents the second leading cause of cancer-related
death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa …

Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

C Gabriele, F Aracri, LE Prestagiacomo… - CLINICAL …, 2023 - iris.unicz.it
Background: Prostate Cancer (PCa) represents the second leading cause of cancer-related
death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa …

Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

C Gabriele, F Aracri, LE Prestagiacomo… - Clinical Proteomics …, 2023 - search.proquest.com
Background Prostate Cancer (PCa) represents the second leading cause of cancer-related
death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa …

Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

C Gabriele, F Aracri, LE Prestagiacomo… - Clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Prostate Cancer (PCa) represents the second leading cause of cancer-related
death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa …

Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

C Gabriele, F Aracri, L Prestagiacomo, M Rota… - Clinical …, 2023 - europepmc.org
Background Prostate Cancer (PCa) represents the second leading cause of cancer-related
death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa …

Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables.

C Gabriele, F Aracri, LE Prestagiacomo… - Clinical …, 2023 - search.ebscohost.com
Abstract Background: Prostate Cancer (PCa) represents the second leading cause of cancer-
related death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa …
[HTML] biomedcentral.com

[HTML][HTML] Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical …

C Gabriele, F Aracri… - Clinical …, 2023 - clinicalproteomicsjournal …
Prostate Cancer (PCa) represents the second leading cause of cancer-related death in men.
Prostate-specific antigen (PSA) serum testing, currently used for PCa screening, lacks the …